Mesothelioma Research Today is a free monthly online journal that collates and summarizes the latest research about Mesothelioma, including details on asbestos, symptoms, treatment, causes.

Antiangiogenic therapies for mesothelioma.

Dowell JE, Kindler HL

University of Texas-Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8852, USA. jonathan.dowell@utsouthwestern.edu

A large body of preclinical evidence suggests that angiogenesis plays a key role in the pathogenesis of malignant mesothelioma. Several mediators of angiogenesis seem to be autocrine growth factors in mesothelioma, and in preclinical models, agents that target angiogenesis produce tumor regression. Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions.

Published 5 December 2005 in Hematol Oncol Clin North Am, 19(6): 1137-45, viii.
Full-text of this article is available online (may require subscription).

© 2005-2008 Mesothelioma Research Today. All Rights Reserved.